Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies
- PMID: 28557600
- DOI: 10.5858/arpa.2016-0547-RA
Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies
Abstract
Context: - Detection of variants in hematologic malignancies is increasingly important because of a growing number of variants impacting diagnosis, prognosis, and treatment response, and as potential therapeutic targets. The use of next-generation sequencing technologies to detect variants in hematologic malignancies in a clinical diagnostic laboratory setting allows for efficient identification of routinely tested markers in multiple genes simultaneously, as well as the identification of novel and rare variants in other clinically relevant genes.
Objective: - To apply a systematic approach to evaluate and validate a commercially available next-generation sequencing panel (TruSight Myeloid Sequencing Panel, Illumina, San Diego, California) targeting 54 genes. In this manuscript, we focused on the parameters that were used to evaluate assay performance characteristics.
Data sources: - Analytical validation was performed using samples containing known variants that had been identified previously. Cases were selected from different disease types, with variants in a range of genes. Panel performance characteristics were assessed and genomic regions requiring additional analysis or wet-bench approaches identified.
Conclusions: - We validated the performance characteristics of a myeloid next-generation sequencing panel for detection of variants. The TruSight Myeloid Sequencing Panel covers more than 95% of target regions with depth greater than 500×. However, because of unique variant types such as large insertions or deletions or genomic regions of high GC content, variants in CEBPA, FLT3, and CALR required supplementation with non-next-generation sequencing assays or with informatics approaches to address deficiencies in performance. The use of multiple bioinformatics approaches (2 variant callers and informatics scripts) allows for maximizing calling of true positives, while identifying limitations in using either method alone.
Similar articles
-
Next-generation sequencing-based panel testing for myeloid neoplasms.Curr Hematol Malig Rep. 2015 Jun;10(2):104-11. doi: 10.1007/s11899-015-0256-3. Curr Hematol Malig Rep. 2015. PMID: 25933675 Review.
-
Targeted next-generation sequencing using a multigene panel in myeloid neoplasms: Implementation in clinical diagnostics.Int J Lab Hematol. 2017 Dec;39(6):604-612. doi: 10.1111/ijlh.12709. Epub 2017 Jul 19. Int J Lab Hematol. 2017. PMID: 28722833
-
Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3. Arch Pathol Lab Med. 2017. PMID: 28557599
-
Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms.PLoS One. 2021 Apr 28;16(4):e0243683. doi: 10.1371/journal.pone.0243683. eCollection 2021. PLoS One. 2021. PMID: 33909614 Free PMC article.
-
The Interpretation of Sequence Variants in Myeloid Neoplasms.Am J Clin Pathol. 2021 Oct 13;156(5):728-748. doi: 10.1093/ajcp/aqab039. Am J Clin Pathol. 2021. PMID: 34155503 Review.
Cited by
-
Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.Cancers (Basel). 2019 Dec 16;11(12):2030. doi: 10.3390/cancers11122030. Cancers (Basel). 2019. PMID: 31888289 Free PMC article.
-
Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design.PLoS One. 2020 Jan 24;15(1):e0227986. doi: 10.1371/journal.pone.0227986. eCollection 2020. PLoS One. 2020. PMID: 31978184 Free PMC article.
-
TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation.Cancers (Basel). 2023 Jun 16;15(12):3210. doi: 10.3390/cancers15123210. Cancers (Basel). 2023. PMID: 37370821 Free PMC article.
-
Nanopore Targeted Sequencing for Rapid Gene Mutations Detection in Acute Myeloid Leukemia.Genes (Basel). 2019 Dec 9;10(12):1026. doi: 10.3390/genes10121026. Genes (Basel). 2019. PMID: 31835432 Free PMC article.
-
The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469. Blood Adv. 2018. PMID: 30327374 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous